| Summary: | 碩士 === 高雄醫學大學 === 醫學系生理學科碩士班 === 103 === Osteoporosis is the common diseases in menopausal women and elderly people, and its incidence just lower than cardiovascular disease. Excessive osteoclastogenesis is one of the main reasons to cause osteoporosis. Recent clinical researches indicated that the patients’ long-term use of anti-depression drugs (Selective Serotonin Reuptake Inhibitor, SSRI) usually with higher risk to suffer osteoporosis. This observation means serotonin, 5-HT, should involve in the regulation of bone metabolism. Previous reports showed that 5-HT 2B receptor (5-HT2BR) is expressed in both osteoblasts and osteoclasts, and which modulate the proliferation and differentiation in osteoblasts. However, the effects of 5-HT2BR in osteoclasts remain unclear. Using RANKL-induced osteoclastogenesis in RAW 264.7 cells as the model, our results presented a positive correlation between the osteoclastogenesis with 5-HT and 5-HT2BR agonist treatment and that decrease SirT1 expression. On the contrary, treatment with specific 5-HT2BR antagonist significantly reduced the osteoclastogenesis and increase SirT1 expression. Treatment with SirT1 agonist significantly reduced the osteoclastogenesis. Taken together, this investigation suggested that 5-HT2BR play an essential role in osteoclastogenesis and may be involved in regulating osteoporosis. Our observations might also provide another direction of prophylaxis and therapy for osteoporosis.
|
|---|
